MET and hepatocellular carcinoma: Emerging evidence has indicated that HGF/MET signaling plays a crucial role on tumor formation, development, maintenance, metastasis as well as the efficacy to systemic therapy, including sorafenib, in HCC 3, 6, 8, 34-36.